Alzamend Neuro Inc. (ALZN) shares declined 5.19% in after-hours on Thursday, September 30, 2021, and closed the daily trading at $2.92. However, in the regular trading session, ALZN’s stock gained 35.09%. The stock volume remained 58.6 million shares. ALZN shares have moved up 17.11% in the past week. Over the past three months, the stock has lost 59.90%. The company has a current market of $293.25 million and its outstanding shares stood at 84.59 million.
Let’s discuss its recent news and developments.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
ALZN provided an update about AL002
On September 30, 2021, Alzamend Neuro, Inc. (ALZN) received a written response to its meeting request relating to its Type B Pre‑Investigational New Drug Application from the U.S. Food and Drug Administration providing a path for Alzamend’s planned clinical development of AL002. AL002 is a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s.
Alzamend is now getting ready to file the IND by the end of November 2021 and initiating the clinical trial of AL002 in the first quarter of 2022.
First-in-Human Clinical Trial for AL001
Earlier on September 13, 2021, (ALZN) announced that the first group of healthy participants have been dosed in a six-month Phase I relative bioavailability study for AL001 for dementia related to Alzheimer’s disease. The trial will determine the potential clinically safe and appropriate dosing for AL001 in future studies.
On August 17, 2021, Alzamend (ALZN) contracted Altasciences to conduct a six-month Phase I relative bioavailability study for AL001 in September 2021.
Investment in ALZN ALOO1
On August 04, 2021, Alzamend Neuro, Inc. (ALZN) announced that Digital Power Lending, LLC which is a wholly-owned subsidiary of Ault Global Holdings, Inc made an additional investment in Alzamend.
The recent FDA reply about AL001 was the reason behind its gains on Thursday but we have no idea why did it face negativity in the after-hours.
About the company
Alzamend Neuro, Inc. (ALZN) is a preclinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s disease. The company has two novel therapeutic drug candidates, AL001 which we have discussed above, and AL002 – a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s disease.